Similarly, a dual-signaling CAR T targeting CD19 and CD123 was created and proved more efficient in tumor eradication in preclinical trials than using CAR Ts with a single signaling moiety (CD19-CAR T cells and CD123-CAR T cells) (18). This evidence concerns the gene CD19 and neoplasm.